Leuthold Core ETF (LCR)
Live price chart, market sentiment, and community perspectives for Leuthold Core ETF (AMEX: LCR).
Live price chart, market sentiment, and community perspectives for Leuthold Core ETF (AMEX: LCR).
As a Hedge Fund PM reviewing LCR's Q2 2026 filings, I note that 18 institutions hold roughly $34.6 million. While 8 funds increased their stakes, the net reduction of one fund and limited new entries suggest a mature holding phase rather than aggressive accumulation. We are monitoring the 50-day moving average around $39.20 to $40.54 for entry signaling.
Looking at the risk profile from a Risk Manager standpoint, LCR's beta of 0.53 highlights its defensive characteristics. However, the thin trading liquidity—with average daily volume hovering near 5,500 shares—introduces execution slippage risks for larger block orders during volatile macroeconomic shifts.
From a Quant perspective, the short interest dynamics on LCR are fascinating but minor in scale. The July spike to 8,108 shares (up 2,686% from a minuscule base of 291) yielded a days-to-cover of 3.4 days against an average volume of 2,401. It indicates episodic short-term hedging rather than a structural short thesis.
As an Options Desk strategist, I observe that LCR lacks active listed options volume in standard reporting fields, meaning position adjustments must be handled strictly via equity blocks. With a net expense ratio of 0.65% and a 1.28% dividend yield, the vehicle functions primarily as a conservative tactical diversifier.
On our trading desk, watching LCR trade near $40.77 with a 52-week high of $40.80 suggests minor resistance at psychological round numbers. With zero first-time institutional investments reported against one exit in recent filings, incoming capital is essentially flat, requiring patience for breakout catalysts.
Evaluating the underlying investment objective, Leuthold Core ETF relies on a tactical asset allocation model that adjusts portfolio weightings as business cycles evolve. The fund's Morningstar rating among 225 Tactical Allocation funds as of June 2026 underpins its risk-adjusted return objective.
Explore plasma cleansing, somatic organ swaps, and BCI.